These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3049817)

  • 1. Protective immunity evoked by locally administered group A streptococcal vaccines in mice.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    J Immunol; 1988 Oct; 141(8):2767-70. PubMed ID: 3049817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 3. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses.
    Bronze MS; Courtney HS; Dale JB
    J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
    Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
    J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci.
    Kapur V; Maffei JT; Greer RS; Li LL; Adams GJ; Musser JM
    Microb Pathog; 1994 Jun; 16(6):443-50. PubMed ID: 7830531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein.
    Beachey EH; Stollerman GH; Johnson RH; Ofek I; Bisno AL
    J Exp Med; 1979 Oct; 150(4):862-77. PubMed ID: 390084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with serum opacity factor (SOF) of Streptococcus pyogenes fails to protect mice against lethal mucosal challenge with a heterologous strain.
    Schulze K; Medina E; Guzmán CA
    Vaccine; 2006 Feb; 24(9):1446-50. PubMed ID: 16289766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes.
    Schulze K; Olive C; Ebensen T; Guzmán CA
    Vaccine; 2006 Aug; 24(35-36):6088-95. PubMed ID: 16828529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization with multivalent group A streptococcal vaccines protects mice against intranasal challenge infections.
    Hall MA; Stroop SD; Hu MC; Walls MA; Reddish MA; Burt DS; Lowell GH; Dale JB
    Infect Immun; 2004 May; 72(5):2507-12. PubMed ID: 15102757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers.
    Fox EN; Waldman RH; Wittner MK; Mauceri AA; Dorfman A
    J Clin Invest; 1973 Aug; 52(8):1885-92. PubMed ID: 4719668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.
    Cleary PP; Matsuka YV; Huynh T; Lam H; Olmsted SB
    Vaccine; 2004 Oct; 22(31-32):4332-41. PubMed ID: 15474726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection.
    Sabharwal H; Michon F; Nelson D; Dong W; Fuchs K; Manjarrez RC; Sarkar A; Uitz C; Viteri-Jackson A; Suarez RS; Blake M; Zabriskie JB
    J Infect Dis; 2006 Jan; 193(1):129-35. PubMed ID: 16323141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of heterologous gram-positive vaccine against lethal upper respiratory tract infection with type M50 group A streptococci in mice.
    Stjernquist-Desatnik A; Kurl DN; Schalén C; Christensen P
    Vaccine; 1990 Apr; 8(2):150-2. PubMed ID: 2110704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group A streptococcal M protein vaccine: protection following immunization via the respiratory tract.
    Waldman RH; Lee JD; Polly SM; Dorfman A; Fox EN
    Dev Biol Stand; 1975; 28():429-34. PubMed ID: 1126582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.